Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Veiligheids- en verdraagbaarheidsstudie van ST-503 voor kleine vezelneuropathie-geassocieerde refractaire pijn

30 oktober 2026 bijgewerkt door: Sangamo Therapeutics

Een multicenter fase 1 dubbelblinde, gerandomiseerde, schijn-gecontroleerde dosis escalatiestudie om de veiligheid en verdraagbaarheid van een enkele dosis intrathecale ST-503 gentherapie te bepalen voor refractaire pijn als gevolg van idiopathische kleine vezelneuropathie (ISFN) (ISFN)

This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN).

ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due to small fiber neuropathy (SFN).

Studie Overzicht

Toestand

Geschorst

Gedetailleerde beschrijving

This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN).

Small fiber neuropathy happens when something damages small nerve fibers in your skin, causing symptoms like painful tingling or burning sensations in your hands and feet. Pain originating in the nerves outside of the brain and spinal cord is defined by doctors as neuropathic pain. Scientists have discovered that certain proteins in our bodies called sodium channels are important for communicating pain signals in nerves, specifically, Nav1.7, Nav1.8 and Nav1.9. This first-in-human study will test the use of a type of experimental treatment called "gene therapy." The primary goal is to determine if it is safe and well tolerated. The second goal is to determine if it reduces the level of refractory pain due to SFN disease. The gene will be delivered into your cells using a special delivery tool called a vector.

Studietype

Ingrijpend

Inschrijving (Geschat)

27

Fase

  • Fase 2
  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Arizona
      • Scottsdale, Arizona, Verenigde Staten, 85260
        • HonorHealth
    • Arkansas
      • Little Rock, Arkansas, Verenigde Staten, 72205
        • University of Arkansas for Medical Sciences
    • California
      • La Jolla, California, Verenigde Staten, 92093
        • The University of California, San Diego
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21218
        • Johns Hopkins University
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02114
        • Massachusetts General Hospital
    • New Hampshire
      • Lebanon, New Hampshire, Verenigde Staten, 03766
        • Dartmouth Hitchcock Medical Center
    • New York
      • New York, New York, Verenigde Staten, 10027
        • Columbia University Irving Medical Center (CUIMC) and New York-Presbyterian Hospital (NYPH)
    • North Carolina
      • Chapel Hill, North Carolina, Verenigde Staten, 27514
        • University of North Carolina Medical Center
    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37235
        • Vanderbilt University
    • Utah
      • Salt Lake City, Utah, Verenigde Staten, 84112
        • University of Utah
    • Virginia
      • Richmond, Virginia, Verenigde Staten, 23284
        • Virginia Commonwealth University

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria

  1. Diagnostic characterization of Small Fiber Neuropathy (SFN) according to the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) criteria.
  2. Medical record documentation that pain is refractory to 2 of 3 categories of first line medical therapy for at ≥ 6 months prior to screening.
  3. Serum sample negative for pre-existing anti-AAV9 antibodies determined by assay detection limit

Exclusion Criteria

  1. Drug- and alcohol-related:

    1. Persons using opioid analgesics for under 3 months or persons who are not on a stable dose of opioids; if on a stable dose, the dose may decrease over the course of the study but should not be increased.
    2. History of known alcohol abuse, opioid analgesic abuse, or illicit drug abuse within 2 years of Screening.
    3. Positive urine test for drugs of abuse (including opiates, benzodiazepines, amphetamines, cocaine, barbiturates, and phencyclidine) without prescription and investigator approval, at Screening and Day -1.
    4. Use of cannabinoids is not permitted.
  2. Persons with Fabry's disease, with erythromelalgia, with peripheral neuropathies due to alcohol or drug toxicity, or with diagnosed channelopathies

  3. Procedure-related:

    1. Contraindications to LP, general anesthesia or sedation
    2. Any medical disorders that, in the opinion of the Investigator, could interfere with LP including but not limited to evidence for a pressure gradient between supratentorial and infratentorial compartments, Arnold-Chiari malformation, bleeding diathesis, clinically significant coagulopathy, thrombocytopenia, increased intracranial pressure, or spine disease or past surgical procedures involving the spine
  4. Infectious disease-related:

    1. Active viral infection or bacterial
    2. A severe infection (e.g., pneumonia, septicemia, central nervous system infections [e.g., meningitis, encephalitis]) within 12 weeks prior to Screening
  5. Hepatic disease- and hepatotoxic medication-related:

    1. Presence of clinically relevant liver disease
    2. Hepatic dysfunction as indicated by one or more of the following: i. Albumin ≤ 3.5 g/dL ii. Total bilirubin > 1.5 x ULN and direct bilirubin ≥0.5 mg/dL iii. Alkaline phosphatase (ALP) > 2 x ULN iv. Alanine transaminase (ALT) or aspartate transaminase (AST) > 1.5 x ULN
    3. Hepatotoxic medications should be avoided during the study period including acetaminophen exceeding 4 gm/day unless essential to patient's treatment, approved by investigator, and hepatic dysfunction is not identified
    4. Hepatotoxic supplement use during the study period
  6. Cancer-related:

    a. History of cancer, including B-cell cancers, within 5 years of Screening

    i. Exceptions to this exclusion are fully excised non-melanoma skin cancers, non-metastatic prostate cancer, and fully treated ductal carcinoma in situ of the breast, provided subject has been stable for at least 6 months

    b. Previous autologous or allogeneic bone marrow transplant, peripheral stem cell transplant or solid organ transplantation

  7. Previously received gene or cellular therapy

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Sham-vergelijker: Schijncontrole studie

Sham Procedure

Experimenteel: Onderzoeksagent

Genomic Medicine

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Incidence and severity of treatment emergent adverse events (TEAEs)
Tijdsspanne: 12 weeks

To assess safety and tolerability of ST-503 over a 12-week post-dosing observation period.

12 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of subjects with pain intensity reduction from baseline at Week 12
Tijdsspanne: 12 weeks
  • 30% in the weekly average of daily pain intensity measurements performed using the PI-NRS

  • 50% in the weekly average of daily pain intensity measurements performed using the PI-NRS

    • Dose of rescue medication use
    • Frequency of rescue medication use
12 weeks
Percentage of subjects at Week 12
Tijdsspanne: 12 weeks
  • Categorized as improved on the patient global impression of change (PGIC) assessment
  • With a ≥ 1-point improvement in suicidal ideation in Columbia Suicide Severity Rating Scale (C-SSRS) responses
12 weeks
Columbia Suicide Severity Rating Scale (CSSRS) Rating
Tijdsspanne: 12 weeks

With a ≥ 1-point decline in suicidal ideation in Columbia Suicide Severity Rating Scale (CSSRS) responses

12 weeks
Overall Pain Intensity Numerical Rating Scale (PI-NRS) score
Tijdsspanne: 12 Weeks

Participants will rate their pain intensity using an 11-point Numerical Rating Scale (0=no pain and 10=worst possible pain) and record their score in an electronic diary.

12 Weeks
Short Form McGill Pain Questionnaire-2 (SF-MQ-2)
Tijdsspanne: 12 Weeks

This pain scale was developed to evaluate chronic neuropathic and non-neuropathic pain in adults. It consists of 22 descriptors of pain in 4 parts (continuous, intermittent, neuropathic, and affective pain types) to be rated from 0-10 with 0 indicating no pain and 10 the worst pain ever during the past week.

12 Weeks
Daily Sleep Interference Score (DSIS)
Tijdsspanne: 12 Weeks

DSIS is assessed on an 11-point NRS, which ranges from 0 (none) to 10 (severe).

12 Weeks
Hospital Anxiety and Depression Scale (HADS)
Tijdsspanne: 12 Weeks

HADS is a screening tool for anxiety and depression in non-psychiatric clinical populations consisting of 14 items (seven each for anxiety and depression). Higher scores correlate with worse symptoms.

12 Weeks
Rasch-Transformed 13-item SFN Symptoms Inventory Questionnaire
Tijdsspanne: 12 Weeks

The 13-item SFN-SIQ evaluates changes in physiological functions such as sweating patterns and incontinence using a four-point Likert scale (0 = never present, 1 = sometimes, 2 = often, and 3 = always present) to get a sum of the grading scores attributed to each of the 13 items with a 0 to 39 range. Higher scores correlate with worse symptoms.

12 Weeks
SFN-specific Rasch-built Overall Disability Scale (SFN-RODS)
Tijdsspanne: 12 Weeks

The 32-item SFN-RODS is a disease-specific interval measure suitable to detect activity limitations and participation restrictions in patients with SFN. The scale ranges from 0 to 64 with higher numbers indicating worse disability.

12 Weeks
36-Item Short Form Health Survey (SF-36) domains and summary scores
Tijdsspanne: 12 Weeks

This measures quality of life measures such as physical functioning, emotional well-being, energy levels, and social functioning. The range is from 0-100 with higher scores being associated with a better perceived quality of life.

12 Weeks
Pain Catastrophizing Questionnaire (PCS)
Tijdsspanne: 12 Weeks

PCS has 13 questions related to rumination, magnification and helplessness with values ranging 0 to 4 for a total possible score of 52. The higher the score the more pain catastrophizing is present.

12 Weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Medical Monitor, Sangamo Therapeutics Inc.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

4 december 2025

Primaire voltooiing (Geschat)

1 juli 2027

Studie voltooiing (Geschat)

1 juli 2028

Studieregistratiedata

Eerst ingediend

30 april 2025

Eerst ingediend dat voldeed aan de QC-criteria

12 mei 2025

Eerst geplaatst (Werkelijk)

20 mei 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

3 november 2026

Laatste update ingediend die voldeed aan QC-criteria

30 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren